HCV | WEBCASTS

Beginning Date

12/20/2016

Ending Date

12/20/2017

0.5

credit

Speakers

Andrew Talal, MD, MPH
Professor and Director, Center for Research
and Clinical Care in Liver Disease
University at Buffalo
Buffalo, NY

Webcast

Webcast must be viewed in its entirety to claim credit.

Accredited by:

This activity is provided by the Chronic Liver Disease Foundation.

Supported by:

This activity Supported by educational grants from AbbVie, Gilead, and Merck.

Target Audience

This educational program is targeted at physicians and other healthcare providers who specialize in the management of patients with addictive disorders.

Educational Objectives

Upon completion of this activity, the participants should be better able to:

•	Review the importance of Hepatitis C screening, diagnosis, and linkage to care
•	Describe new developments in HCV that have eliminated many of the previous barriers to pursuit of HCV therapy in individuals with substance use disorders
•	Develop strategies for the engagement of patients with substance use disorders into HCV care

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation (CLDF). The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest:

All faculty and staff involved in the planning or presentation of continuing education activities provided by the Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. John Bayliss, VP, Business Development, spouse is an employee of Amgen, Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation (CLDF) have no relationships to disclose.

The opinions expressed during the enduring material are those of the faculty and do not necessarily represent the views of the Annenberg Center for Health Sciences at Eisenhower. The information is presented for the purpose of advancing the attendees' professional development.

Learner Assurance Statement

The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members' significant relationships with drug or device manufacturer(s). The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

Presenter Disclosure Statement:

Andrew Talal, MD, MPH
Grants/Research Support: Merck, Gilead, Abbott, AbbVie, Intercept, Tobira, Conatus
Committee/Advisor: Merck, Abbott Diagnostics, AbbVie, Chronic Liver Disease Foundation